Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 25, 2026 09:00 ET | Source: Arrakis Therapeutics

Arrakis Therapeutics Announces CEO Transition with Mark DeLong Appointed as New CEO

— Mark DeLong to lead Arrakis as it becomes a clinical-stage company, advancing its lead oral RNA-targeted small molecule to treat myotonic dystrophy type 1 (DM1) — — Michael Gilman retires from role...
December 03, 2025 08:00 ET | Source: Arrakis Therapeutics

Arrakis Therapeutics Presents Data Highlighting Progress of Oral RNA-targeted Small Molecule to Treat Myotonic Dystrophy Type 1 (DM1)

Preclinical in vivo data demonstrate hyper-precise mechanism directly targets the disease-causing mRNA repeats leading to correction of splicing defects and reversal of myotonia Oral administration...